EGFR and neoplasm: One possible explanation for the similar behaviours of BRAFnon-V600E and BRAFV600E-mutated tumours in terms of unresponsiveness to anti-EGFR antibody treatment may be the incomplete blockade of the MEK pathway by modestly upregulated kinase activity of BRAF and/or by additional signalling through wild-type CRAF (Wan et al, 2004).